VRTX · News · 20260810N
Guidance and Outlook
VERTEX PHARMACEUTICALS INC / MA · 2026-08-10 · Importance 83 · Surprise 60 · In source text
Vertex raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion after reporting stronger-than-expected second-quarter results. The revised outlook reflects continued demand for its cystic fibrosis portfolio and contributions from newer products including CASGEVY and JOURNAVX. Analysts cited potential revenue of approximately US$17.2 billion by 2029, although that figure is an external projection rather than company guidance.
Key facts
- Vertex Pharmaceuticals raised its 2026 revenue guidance to US$13.10–US$13.20 billion. source
- Vertex Pharmaceuticals slightly raised its full-year revenue guidance after Q2 2026 results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Vertex Pharmaceuticals raised its 2026 revenue guidance to US$13.10–US$13.20 billion. |